# Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)

> **NCT02291874** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 100 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Ipragliflozin

## Key facts

- **NCT ID:** NCT02291874
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-08
- **Primary completion:** 2016-07-07
- **Final completion:** 2016-07-07
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02291874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02291874, "Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02291874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*